Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema
Ampio Pharmaceuticals, Inc. today announced the initiation of a Phase II clinical trial of Optina for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus.
Read more...
ThromboGenics To Present Results Of Second Phase III Trial Of Microplasmin At The 28th Annual Meeting Of The American ...
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS ...
Read more...
|